Affymax folds after drug withdrawal


Biotech firm Affymax is to be dissolved after post-marketing reports of serious hypersensitivity reactions prompted it to recall its anaemia drug Omontys (peginesatide).

An investigation in conjunction with its marketing partner Takeda found no quality or manufacturing issues with Omontys. However, it also failed to identify any specific root cause for the allergic reactions, so the companies were left with no option but to withdraw the product. Takeda has broken off its marketing agreement with Affymax, effective from 10 September and, subject to shareholder approval, the company will be liquidated .

Omontys is a PEGylated peptide drug used to treat anaemia caused by chronic kidney disease.


Related Content

Optical tweezers extract biomolecule folding secrets

9 April 2016 Research

news image

Pioneering ‘transition path’ analysis studies mad cow disease-causing prions

Eye drops show promise treating cataracts and even reversing damage

6 November 2015 Research

news image

Sterol compound can ‘dissolve’ mis-folded proteins to help clear the lens offering hope to 100 million in developing worl...

Most Commented

New antibiotic picked from nose bacteria

27 July 2016 Research

news image

Discovery suggests human microbiome may be an untapped source of antimicrobial compounds

Beyond element 118: the next row of the periodic table

29 January 2016 News and Analysis

news image

A technological leap may be called for to expand the number of elements in existence